The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions
Timeframe: Up to Day 64 (7 days after each injection)
Number of Participants with Unsolicited Adverse Events (AEs)
Timeframe: Up to Day 85 (28 days after each injection)
Number of Participants with Serious AEs, AEs Leading to Discontinuation of Study Vaccine or Withdrawal From the Study, and AEs of Special Interest
Timeframe: Day 1 to End of Study (up to a maximum of Day 1113)
Number of Participants with Medically Attended AEs
Timeframe: Day 1 to Day 393 (12 months after last study injection)